Kalydeco® (ivacaftor) – Expanded indication
April 30, 2019 - Vertex announced the FDA approval of Kalydeco (ivacaftor), for the treatment of cystic fibrosis (CF) in patients age 6 months and older who have one mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) gene that is responsive to ivacaftor potentiation based on clinical and/or in vitro assay data
Top